Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-02-20
Tempus AI, Inc.
Tempus provides genetic testing to providers and licenses de-identified clinical/molecular data plus related trial and AI-application services to life-sciences customers.
ai biotech healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From testing volume to verified precision-medicine rails
A credible path exists to compound clinical data into a higher-margin platform, but the market will demand proof of renewability, workflow adoption, and financing discipline over the next 12–18 months.

Analysis

Thesis
Tempus can compound a defensible clinic-to-data flywheel: grow reimbursed diagnostics volume to refresh proprietary datasets, then monetize them through higher-margin life-sciences + workflow products where “verification + permissioning” (not raw cognition) is what customers pay for.
Last Economy Alignment
As AI makes analysis cheap, Tempus’ value is in owned clinical data rights, regulated trust surfaces, and embedded workflows that create durable, auditable distribution.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.1x (from 5 most recent analyses)
Reasoning
The non-linear upside is a shift in what customers pay for: from “reports and analytics” to “verified, compliance-ready decisioning + enrollment rails” that sit inside clinical and pharma workflows. If Tempus proves (i) durable diagnostics volume + reimbursement, (ii) repeatable conversion/renewal of contracted life-sciences demand, and (iii) attach of regulated workflow apps, revenue can scale faster than headcount and hold a platform-like multiple rather than a commodity lab multiple.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
Tempus’ main risks are (1) regulated/reimbursed throughput (what can be deployed and paid for), (2) durable value capture in life-sciences contracts as datasets commoditize, and (3) financing flexibility given debt maturities and ongoing investment needs. Execution risk is amplified by the need to simultaneously scale labs, renew/convert contracted demand, and productize workflow deployments.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.49
They control valuable clinical data rights and have regulated footholds that make their outputs more trusted than generic AI. The upside compounds if workflow adoption increases data refresh and verification value, but regulation and refinancing can throttle speed.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$87.92
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case